Erythroid Neoplasm — Trials

Erythroid Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 48
Recruiting: 25
Ph III recruiting: 7
Growth YoY: —
Industry share: 48%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (50)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02805868	Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis	withdrawn	Early Phase 1	0	Northwestern UniversityOTHER	0	Oct 24, 2016	clinicaltrials

Data updated 22 days agoSource updated Oct 24, 2016source: clinicaltrials